JP2022519583A - 神経変性疾患を検出する方法 - Google Patents

神経変性疾患を検出する方法 Download PDF

Info

Publication number
JP2022519583A
JP2022519583A JP2021544901A JP2021544901A JP2022519583A JP 2022519583 A JP2022519583 A JP 2022519583A JP 2021544901 A JP2021544901 A JP 2021544901A JP 2021544901 A JP2021544901 A JP 2021544901A JP 2022519583 A JP2022519583 A JP 2022519583A
Authority
JP
Japan
Prior art keywords
exosome
binding
biomarker
subject
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021544901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519583A5 (enExample
Inventor
ホエリン シャオ
ツー ジュン カリーヌ リム
ヤン チャン
リ－シアン クリストファー チェン
ジー ピン ロー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University Hospital Singapore Pte Ltd
Original Assignee
National University Hospital Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Hospital Singapore Pte Ltd filed Critical National University Hospital Singapore Pte Ltd
Publication of JP2022519583A publication Critical patent/JP2022519583A/ja
Publication of JP2022519583A5 publication Critical patent/JP2022519583A5/ja
Priority to JP2024207019A priority Critical patent/JP2025029000A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/55—Specular reflectivity
    • G01N21/552—Attenuated total reflection
    • G01N21/553—Attenuated total reflection and using surface plasmons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/55—Specular reflectivity
    • G01N21/552—Attenuated total reflection
    • G01N21/553—Attenuated total reflection and using surface plasmons
    • G01N21/554—Attenuated total reflection and using surface plasmons detecting the surface plasmon resonance of nanostructured metals, e.g. localised surface plasmon resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/553—Metal or metal coated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021544901A 2019-01-31 2020-01-30 神経変性疾患を検出する方法 Pending JP2022519583A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024207019A JP2025029000A (ja) 2019-01-31 2024-11-28 神経変性疾患を検出する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201900940Y 2019-01-31
SG10201900940Y 2019-01-31
PCT/IB2020/050764 WO2020157705A1 (en) 2019-01-31 2020-01-30 Method of detecting a neurodegenerative disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024207019A Division JP2025029000A (ja) 2019-01-31 2024-11-28 神経変性疾患を検出する方法

Publications (2)

Publication Number Publication Date
JP2022519583A true JP2022519583A (ja) 2022-03-24
JP2022519583A5 JP2022519583A5 (enExample) 2023-02-02

Family

ID=71841387

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021544901A Pending JP2022519583A (ja) 2019-01-31 2020-01-30 神経変性疾患を検出する方法
JP2024207019A Pending JP2025029000A (ja) 2019-01-31 2024-11-28 神経変性疾患を検出する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024207019A Pending JP2025029000A (ja) 2019-01-31 2024-11-28 神経変性疾患を検出する方法

Country Status (6)

Country Link
US (1) US20220397580A1 (enExample)
EP (1) EP3918327A4 (enExample)
JP (2) JP2022519583A (enExample)
CN (2) CN113614531A (enExample)
SG (1) SG11202107238UA (enExample)
WO (1) WO2020157705A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120121584A (zh) 2019-01-31 2025-06-10 新加坡国立大学 传感器芯片及其方法
EP4428245A4 (en) * 2021-11-04 2025-04-02 Toppan Holdings Inc. Method for detecting amyloid-beta bound to brain-neuronal-cell-derived exosome in blood, kit for detection of amyloid-beta bound to brain-neuronal-cell-derived exosome in blood, and method for evaluating accumulation level of amyloid-beta in brain
WO2023232108A1 (zh) * 2022-06-02 2023-12-07 浙江大学医学院附属第一医院 诊断及鉴别诊断非阿尔兹海默病认知障碍的方法、系统、组合物和试剂盒
WO2025117465A1 (en) * 2023-11-27 2025-06-05 New York University Tau is a low affinity receptor of glucocorticoid and needed for glucocorticoid-caused bone loss
WO2025122650A1 (en) * 2023-12-04 2025-06-12 Sunbird Bio, Inc. Extracellular vesicle-based biomarker detection
CN118348260B (zh) * 2024-05-13 2025-02-25 香港中文大学（深圳） 一种帕金森病诊断标志物组合及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535283A (ja) * 2013-10-24 2016-11-10 ナノソミックス・インコーポレイテッドＮａｎｏＳｏｍｉＸ， Ｉｎｃ． アルツハイマー病および他の神経変性障害のためのバイオマーカーおよび診断方法
WO2017087467A1 (en) * 2015-11-20 2017-05-26 Exosome Sciences, Inc. Exosomal tau as a biomarker for brain disorders
WO2017124000A1 (en) * 2016-01-14 2017-07-20 The Regents Of The University Of California 3d-exoquant method for the analysis of surface molecules and quantification of tissue-specific exosomes in biological fluids
US20180238910A1 (en) * 2017-02-22 2018-08-23 Korea Institute Of Science And Technology Methods for providing information relevant to diagnosis of neurodegenerative disorder
WO2018218090A1 (en) * 2017-05-24 2018-11-29 Nanosomix, Inc. Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2963791B1 (fr) * 2010-08-11 2012-09-21 Assist Publ Hopitaux De Paris Methode de diagnostic des maladies neurodegeneratives
US20140256793A1 (en) * 2011-10-14 2014-09-11 National University Corporation Hokkaido University MEDICAMENT FOR DISEASES ASSOCIATED WITH AMYLOID beta AND SCREENING THEREOF
CN106062559B (zh) * 2014-06-27 2018-12-14 北京新源长青生物科技有限公司 用于富集cns来源的外泌体的方法
EP3307890A1 (en) * 2015-06-10 2018-04-18 Board of Regents, The University of Texas System Use of exosomes for the treatment of disease
WO2017193115A1 (en) * 2016-05-06 2017-11-09 Nanosomix, Inc. Synaptic protein biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535283A (ja) * 2013-10-24 2016-11-10 ナノソミックス・インコーポレイテッドＮａｎｏＳｏｍｉＸ， Ｉｎｃ． アルツハイマー病および他の神経変性障害のためのバイオマーカーおよび診断方法
WO2017087467A1 (en) * 2015-11-20 2017-05-26 Exosome Sciences, Inc. Exosomal tau as a biomarker for brain disorders
WO2017124000A1 (en) * 2016-01-14 2017-07-20 The Regents Of The University Of California 3d-exoquant method for the analysis of surface molecules and quantification of tissue-specific exosomes in biological fluids
US20180238910A1 (en) * 2017-02-22 2018-08-23 Korea Institute Of Science And Technology Methods for providing information relevant to diagnosis of neurodegenerative disorder
WO2018218090A1 (en) * 2017-05-24 2018-11-29 Nanosomix, Inc. Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders

Also Published As

Publication number Publication date
US20220397580A1 (en) 2022-12-15
JP2025029000A (ja) 2025-03-05
EP3918327A4 (en) 2022-11-23
WO2020157705A1 (en) 2020-08-06
CN120870569A (zh) 2025-10-31
EP3918327A1 (en) 2021-12-08
CN113614531A (zh) 2021-11-05
SG11202107238UA (en) 2021-07-29

Similar Documents

Publication Publication Date Title
Lim et al. Subtyping of circulating exosome-bound amyloid β reflects brain plaque deposition
JP2022519583A (ja) 神経変性疾患を検出する方法
US12523664B2 (en) Sensor chip and methods thereof
Sharma et al. Ultrasensitive probeless capacitive biosensor for amyloid beta (Aβ1-42) detection in human plasma using interdigitated electrodes
Kim et al. Antibody-based magnetic nanoparticle immunoassay for quantification of Alzheimer’s disease pathogenic factor
Kim et al. Comparative analyses of plasma amyloid-β levels in heterogeneous and monomerized states by interdigitated microelectrode sensor system
Lu et al. A probe for NIR-II imaging and multimodal analysis of early Alzheimer’s disease by targeting CTGF
CN102933966A (zh) 阿尔茨海默病的新型诊断制剂
CN113366317A (zh) 用于囊泡货物标记和检测的系统和方法
US12613188B2 (en) Methods and systems of enhancing electromagnetic radiation signals from extracellular vesicles
Yuyama et al. Immuno-digital invasive cleavage assay for analyzing Alzheimer’s amyloid ss-bound extracellular vesicles
JP4624559B2 (ja) 初期ｃｎｓダメージのマーカーとしてのタウ
US20240410876A1 (en) Extracellular vesicle drug analysis for real-time monitoring of targeted therapy
US20230221252A1 (en) Methods and devices for characterizing nanovesicles and bound or associated targets thereof
Fukutomi et al. Single-extracellular-vesicle detection with a plasmonic chip and enhanced fluorescence microscopy
KR102953357B1 (ko) 센서 칩 및 그의 방법
Song et al. Direct and selective nanosensor for amyloid-β oligomers in serum for Alzheimer's disease diagnosis
Zheng et al. Colorimetric aptasensor based on temporally controllable light-stimulated oxidase-mimicking fluorescein for the sensitive detection of exosomes in mild conditions
WO2024206493A1 (en) Molecular analysis of extracellular vesicles (evs) for the detection of idiopathic pulmonary fibrosis
Xin et al. Detection and Profiling of Neurodegenerative Disease-Related Extracellular Vesicles through Membrane and Cargo Proteins
KR102833107B1 (ko) 생체분자를 기반으로 하는 금속 나노 구조체 및 이를 이용한 나노 플라즈모닉 바이오 센서
Yan Plasmonic Biosensor Platforms for Molecular Analy-ses of Circulating Extracellular Vesicles
WO2025080712A1 (en) Plasmon-enhanced biosensing of extracellular vesicles
JP2025524969A (ja) 細胞外小胞からの電磁放射線シグナルを増強する方法およびシステム
WO2024108311A1 (en) Extracellular vesicles for the diagnosis of alzheimer's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230124

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231012

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241030

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241223